文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者应激性溃疡预防的疗效与安全性:随机试验的网络荟萃分析

Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials.
PubMed 文献 · Intensive Care Med · 2017-12-04
一句话结论中等质量证据显示PPI预防临床重要消化道出血最有效,但可能增加肺炎风险,常规应激性溃疡预防的获益与风险平衡存疑。

该网络荟萃分析纳入57项RCT、7293例重症患者,比较PPI、H2RA、硫糖铝和安慰剂用于应激性溃疡预防。PPI预防临床重要消化道出血优于H2RA(OR 0.38)、硫糖铝(OR 0.30)和安慰剂(OR 0.24),均为中等质量证据。PPI较H2RA(OR 1.27)、硫糖铝(OR 1.65)和安慰剂(OR 1.52)可能增加肺炎风险,均为中等质量证据。各干预间死亡率可能相似。作者认为常规应激性溃疡预防的获益与风险平衡存疑。

要点

  • PPI预防临床重要消化道出血优于H2RA(OR 0.38,95%CI 0.20-0.73)、硫糖铝(OR 0.30,95%CI 0.13-0.69)和安慰剂(OR 0.24,95%CI 0.10-0.60),中等质量证据。
  • PPI较H2RA可能增加肺炎风险(OR 1.27,95%CI 0.96-1.68),较硫糖铝(OR 1.65,95%CI 1.20-2.27)和安慰剂(OR 1.52,95%CI 0.95-2.42)也可能增加,中等质量证据。
  • H2RA、硫糖铝和安慰剂之间无令人信服的差异。
  • 各干预间死亡率可能相似(中等质量证据)。
  • 作者认为常规使用应激性溃疡预防的获益与风险平衡存疑。

适用人群与场景

  • 重症监护病房的危重症患者。

研究设计与关键结果

  • 研究类型:随机对照试验的网络荟萃分析;纳入57项试验,共7293例重症患者。
  • PPI预防临床重要消化道出血优于H2RA(OR 0.38,95%CI 0.20-0.73)、硫糖铝(OR 0.30,95%CI 0.13-0.69)和安慰剂(OR 0.24,95%CI 0.10-0.60),均为中等质量证据。
  • PPI较H2RA可能增加肺炎风险(OR 1.27,95%CI 0.96-1.68),较硫糖铝(OR 1.65,95%CI 1.20-2.27)和安慰剂(OR 1.52,95%CI 0.95-2.42)也可能增加,均为中等质量证据。
  • H2RA、硫糖铝和安慰剂之间无令人信服的差异。
  • 各干预间死亡率可能相似(中等质量证据)。

证据类型、等级与局限

  • 证据类型:随机对照试验的网络荟萃分析;证据质量:中等质量证据。
  • 局限:各研究基线出血风险估计差异显著;仅一项研究报告艰难梭菌感染;肺炎定义差异很大;大多数硫糖铝研究早于肺炎预防策略。

对床旁实践的改变

  • 作者认为,常规使用应激性溃疡预防的获益与风险平衡存疑。
  • PPI预防临床重要消化道出血最有效,但可能增加肺炎风险,临床决策需权衡出血与肺炎风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Stress ulcer prophylaxis (SUP) is commonly prescribed in the intensive care unit. However, data from systematic reviews and conventional meta-analyses are limited by imprecision and restricted to direct comparisons. We conducted a network meta-analysis of randomized clinical trials (RCTs) to examine the safety and efficacy of drugs available for SUP in critically ill patients.

METHODS: We searched MEDLINE, EMBASE, and the Cochrane Library Central Register of Controlled Trials through April 2017 for randomized controlled trials that examined the efficacy and safety of proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), and sucralfate for SUP in critically ill patients. No date or language restrictions were applied. Data on study characteristics, methods, outcomes, and risk of bias were abstracted by two reviewers.

RESULTS: Of 96 potentially eligible studies, we included 57 trials enrolling 7293 patients. The results showed that PPIs are probably more effective for preventing clinically important gastrointestinal bleeding (CIB) than H2RAs [odds ratio (OR) 0.38; 95% confidence interval (95% CI) 0.20, 0.73], sucralfate (OR 0.30; 95% CI 0.13, 0.69), and placebo (OR 0.24; 95% CI 0.10, 0.60) (all moderate quality evidence). There were no convincing differences among H2RA, sucralfate, and placebo. PPIs probably increase the risk of developing pneumonia compared with H2RAs (OR 1.27; 95% CI 0.96, 1.68), sucralfate (OR 1.65; 95% CI 1.20, 2.27), and placebo (OR 1.52; 95% CI 0.95, 2.42) (all moderate quality). Mortality is probably similar across interventions (moderate quality). Estimates of baseline risks of bleeding varied significantly across studies, and only one study reported on Clostridium difficile infection. Definitions of pneumonia varied considerably. Most studies on sucralfate predate pneumonia prevention strategies.

CONCLUSIONS: Our results provide moderate quality evidence that PPIs are the most effective agents in preventing CIB, but they may increase the risk of pneumonia. The balance of benefits and harms leaves the routine use of SUP open to question.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Alhazzani W, Alshamsi F, Belley-Cote E, et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive Care Med. 2017. PMID: 29199388. doi:10.1007/s00134-017-5005-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。